Edmond DE Rothschild Holding S.A. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 19.1% during the third quarter, Holdings Channel.com reports. The fund owned 99,441 shares of the biopharmaceutical company’s stock after purchasing an additional 15,931 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Gilead Sciences were worth $14,822,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Client 1ST Advisory Group LLC raised its position in Gilead Sciences by 4.0% during the third quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 69 shares during the period. Bfsg LLC grew its position in shares of Gilead Sciences by 7.7% in the third quarter. Bfsg LLC now owns 1,003 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 72 shares during the period. Grove Bank & Trust grew its position in shares of Gilead Sciences by 1.2% in the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock valued at $946,000 after purchasing an additional 74 shares during the period. Somerset Trust Co grew its position in shares of Gilead Sciences by 1.0% in the second quarter. Somerset Trust Co now owns 7,778 shares of the biopharmaceutical company’s stock valued at $983,000 after purchasing an additional 80 shares during the period. Finally, Triumph Capital Management increased its stake in shares of Gilead Sciences by 2.2% during the second quarter. Triumph Capital Management now owns 3,687 shares of the biopharmaceutical company’s stock worth $466,000 after purchasing an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on GILD. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Cantor Fitzgerald raised their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Scotiabank lifted their price objective on Gilead Sciences from $177.00 to $200.00 and gave the stock a “sector outperform” rating in a report on Friday, October 30th. BMO Capital Markets reiterated an “outperform” rating and set a $184.00 price objective on shares of Gilead Sciences in a research note on Friday, October 30th. Finally, Needham & Company LLC set a $175.00 price objective on Gilead Sciences in a research note on Friday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $171.63.
View Our Latest Report on Gilead Sciences
Insider Activity at Gilead Sciences
In other Gilead Sciences news, EVP Wettan Keeley M. Cain sold 3,399 shares of the business’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $164.11, for a total transaction of $557,809.89. Following the sale, the executive vice president directly owned 5,360 shares in the company, valued at $879,629.60. This represents a 38.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the completion of the transaction, the insider directly owned 110,684 shares of the company’s stock, valued at approximately $18,877,156.20. The trade was a 20.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 237,709 shares of company stock worth $39,799,137. Company insiders own 0.30% of the company’s stock.
Gilead Sciences Trading Down 1.4%
Shares of GILD opened at $166.53 on Friday. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $176.58. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. The firm’s fifty day moving average is $156.80 and its two-hundred day moving average is $142.34. The stock has a market cap of $206.55 billion, a PE ratio of -52.70 and a beta of 0.35.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.47 EPS. Research analysts forecast that Gilead Sciences, Inc. will post -0.97 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.
Gilead Sciences Profile
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Read More
- Five stocks we like better than Gilead Sciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
